Search

Author/Creator Legenne, Philippe

1. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Issue 3 (June 2020)

Authors:
Atkinson, Victoria; Sandhu, Shahneen; Hospers, Geke; Long, Georgina V.; Aglietta, Massimo; Ferrucci, Pier F.; Tulyte, Skaiste; Cappellini, Gian Carlo Antonini; Soriano, Virtudes; Ali, Sayed; Poprach, Alexandr; Cesas, Alvydas; Rodriguez-Abreu, Delvys; Lau, Mike; de Jong, Egbert; Legenne, Philippe;...
Journal:
Melanoma research
Issue:
Volume 30:Issue 3(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program. Issue 5 (October 2019)

Authors:
Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; Cebon, Jonathan; Ferrucci, Pier Francesco; Aglietta, Massimo; Neyns, Bart; Chiarion-Sileni, Vanna; Lindsay, Colin R.; Del Vecchio, Michele; Linardou, Helen; Merelli, Barbara; Tonini, Giuseppe; Atkinson, Victoria; Freivogel, Klaus; ...
Journal:
Melanoma research
Issue:
Volume 29:Issue 5(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Issue 12 (December 2016)

Authors:
Long, Georgina V; Grob, Jean-Jacques; Nathan, Paul; Ribas, Antoni; Robert, Caroline; Schadendorf, Dirk; Lane, Stephen R; Mak, Carmen; Legenne, Philippe; Flaherty, Keith T; Davies, Michael A
Journal:
Lancet oncology
Issue:
Volume 17:Issue 12(2016:Dec.)
Page Start:
1743
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 1130. Ensovibep antiviral activity in ambulatory patients with COVID-19 is independent of baseline anti-SARS-CoV-2 antibodies and exhibits minimal selective pressure – Results from the placebo-controlled EMPATHY trial. (15th December 2022)

Authors:
Abrishamian, Luis; Bonten, Marc; Chandra, Richa; Elango, Damodaran Solai; Fustier, Pierre; Gedif, Kinfemichael; Goncalves, Susana; Igbinadolor, Awawu; Kingsley, Jeff; Knutson, Charles G; Kukkaro, Petra; Kumarasamy, Nagalingeswaran; Legenne, Philippe; Mekebeb-Reuter, Martha; Ramanathan, Krishnan; ...
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗